Previous close | 343.40 |
Open | 343.50 |
Bid | 345.74 x 800 |
Ask | 358.57 x 800 |
Day's range | 342.73 - 347.98 |
52-week range | 206.19 - 376.72 |
Volume | |
Avg. volume | 445,312 |
Market cap | 25.702B |
Beta (5Y monthly) | 1.09 |
PE ratio (TTM) | 47.29 |
EPS (TTM) | 7.32 |
Earnings date | 26 Jul 2023 - 31 Jul 2023 |
Forward dividend & yield | 0.76 (0.22%) |
Ex-dividend date | 25 Jul 2023 |
1y target est | 369.22 |
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Revvity's (RVTY) EUROIMMUN launches UNIQO 160, a new automated system for autoimmune disease diagnostics using indirect immunofluorescence test.
Cooper Companies' (COO) second-quarter fiscal 2023 revenues reflect a solid segmental performance despite a year-over-year decline in earnings.
Stryker (SYK) successfully completes first surgical case using its Q Guidance system with Cranial Guidance software. An Early Product Surveillance is underway for the combined technology.
Abbott's (ABT) MONITOR-HF is the third randomized, controlled trial that will provide significant health benefits to indicated heart failure patients.
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Investors are optimistic about STERIS (STE) on strong segmental growth.
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
West Pharmaceutical Services' (NYSE:WST) stock is up by a considerable 35% over the past three months. Since the market...
West Pharmaceutical's (WST) first-quarter results reflect a sustained recovery in non-COVID-19 demand amid dismal overall performance.
West Pharmaceutical (WST) delivered earnings and revenue surprises of 18.56% and 2.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
West Pharmaceutical Services, The Cooper Companies and Henry Schein have been highlighted in this Industry Outlook article.
Does West Pharmaceutical Services (WST) have what it takes to be a top stock pick for momentum investors? Let's find out.
Medical Device companies' Q1 results are likely to reflect strength in customer demand. Let's see how WST, DXCM and BAX are placed ahead of their earnings releases.
Here, we discuss three stocks from the Dental Supplies industry that are likely to create wealth for investors. These include WST, COO and HSIC.
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LabCorp (LH) delivered earnings and revenue surprises of -4.26% and 0.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
West Pharmaceutical's (WST) first-quarter 2023 results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements might have hurt the top and bottom lines.
BDX vs. WST: Which Stock Is the Better Value Option?
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company...
BDX vs. WST: Which Stock Is the Better Value Option?
Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex concerns persist.
Today we're going to take a look at the well-established West Pharmaceutical Services, Inc. ( NYSE:WST ). The company's...
HSIC vs. WST: Which Stock Is the Better Value Option?